EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Relationship of retinal zone and plus severity with the requirement of re-treatment in bevacizumab-treated eyes for retinopathy of prematurity

Sadik Etka Bayramoglu, Nihat Sayin, Ibrahim Kocak

Ophthalmic Research · 2025

DOI: 10.1159/000544710 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Ophthalmic Research, 2025. Verfasst von Sadik Etka Bayramoglu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Ophthalmology Department, Health Science University Kanuni Sultan Suleyman Training, and Research Hospital, Istanbul, Turkey. Hauptthemen laut MEDLINE: Bevacizumab, Retinopathy of Prematurity, Angiogenesis Inhibitors, Retina. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Study aims to investigate the relationship between the location of retinal vascularization and plus severity with re-treatment rates in intravitreal bevacizumab (IVB) treated eyes.

Methods

For this retrospective, observational study, 200 eyes treated with IVB for Type 1 retinopathy of prematurity (ROP) and aggressive-ROP were included. The pre-treatment retinal vascularization was evaluated by analyzing quantitative measurements of optic disc to fovea distance (DFD), disc diameter, and shortest and longest distance between the optic disc and ridge of wide-field fundus photographs (WFPs). Plus severity was qualified in five grades such as normal, pre-plus, mild plus, moderate plus, and severe plus, by evaluating WFPs. Re-treatments up to 60 weeks postmenstrual age (PMA) were evaluated. Re-treated eyes up to first month after initial treatment were labeled as early re-treatment group, and re-treated eyes after the first month of initial treatment up to 60 weeks PMA were labeled as middle term re-treated group.

Results

36% of eyes had zone Ⅰ, 64% of eyes had zone Ⅱ disease, and 42% eyes had mild plus disease. Forty-three (21.5%) eyes of 23 infants underwent re-treatment prior to 60 weeks PMA. Thirteen eyes and 30 eyes were in the early and middle term re-treated groups, respectively. In middle term re-treated group, 27 (13.5%) eyes re-treated for progressive reactivated disease, and 3 (1.5%) eyes re-treated for prophylactic purposes. Advanced pre-treatment retinal vascularization and high birth weight were negatively associated with the re-treatment rate (p=0.016, odds ratio=0.774; p=0.041, odds ratio=0.999, respectively). There was a positive association between the re-treatment rate and pre-treatment plus severity (p=0.044, odds ratio =1.449). The lower ratio of shortest distance between the optic disc and ridge to DFD was considered as an independent predictive variable for higher rate of re-treatment (p=0.002; odds ratio: 0.450).

Conclusion

The location of retinal vascularization and plus disease showed a wide distribution in bevacizumab treated eyes. Graded evaluation of retinal vascularization and plus severity may help predict the need for additional treatment. Unresponsiveness to the initial treatment, increased fibrotic activity, progressive reactivated stage 2-3 ROP and extraretinal new vessels, and prophylactic purposes were the main re-treatment indications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabRetinopathy of PrematurityAngiogenesis InhibitorsRetinaHumansRetrospective StudiesIntravitreal InjectionsFemaleMaleInfant, NewbornGestational AgeSeverity of Illness IndexVascular Endothelial Growth Factor AFollow-Up Studies

Stichwörter der Autor:innen

BevacizumabPediatric retinaPlus diseaseReactivationRetinal zoneRetinopathy of prematurity

Substanzen

BevacizumabAngiogenesis InhibitorsVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Ophthalmology Department, Health Science University Kanuni Sultan Suleyman Training, and Research Hospital, Istanbul, Turkey.

Zitieren

APA

Bayramoglu, S. E., Sayin, N., & Kocak, I. (2025). Relationship of retinal zone and plus severity with the requirement of re-treatment in bevacizumab-treated eyes for retinopathy of prematurity. Ophthalmic Research. https://doi.org/10.1159/000544710

Vancouver

Bayramoglu SE, Sayin N, Kocak I. Relationship of retinal zone and plus severity with the requirement of re-treatment in bevacizumab-treated eyes for retinopathy of prematurity. Ophthalmic Research. 2025. doi:10.1159/000544710

BibTeX
@article{Bayramoglu2025,
  author = {Bayramoglu, Sadik Etka and Sayin, Nihat and Kocak, Ibrahim},
  title = {Relationship of retinal zone and plus severity with the requirement of re-treatment in bevacizumab-treated eyes for retinopathy of prematurity},
  journal = {Ophthalmic Research},
  year = {2025},
  doi = {10.1159/000544710}
}
Kostenlos starten →